ERBB2 and metastatic melanoma: Therefore, the success of Herceptin® in the treatment of breast cancer suggests its potential role in the treatment of melanoma expressing HER2, although some evidence suggests that therapy specifically targeting HER2 may not provide the benefit for patients with metastatic melanoma or as an adjuvant therapy for melanoma patients at high risk for recurrence [19].